Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
EQ Equillium Inc
- Stocks
- Healthcare
- NASDAQ: EQ
Price (delayed)
$0.369
Market cap
$13.18M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.4
Enterprise value
-$1.03M
Equillium is a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders with high unmet medical need. Equillium is developing
Highlights
Equillium's debt has shrunk by 59% YoY and by 23% QoQ
The quick ratio has grown by 44% YoY but it has contracted by 32% from the previous quarter
The EPS has dropped by 74% since the previous quarter and by 14% year-on-year
EQ's net income has dropped by 73% since the previous quarter and by 15% year-on-year
Key stats
What are the main financial stats of EQ
Market
Valuations
Earnings
Shares outstanding
35.72M
Market cap
$13.18M
Enterprise value
-$1.03M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.24
Price to sales (P/S)
0.43
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-0.03
Revenue
$30.41M
Gross profit
$30.41M
Operating income
-$14.35M
Net income
-$13.99M
EBIT
-$13.63M
EBITDA
-$13.49M
Free cash flow
-$18.47M
Per share
Balance sheet
Liquidity
EPS
-$0.4
EPS diluted
-$0.4
Free cash flow per share
-$0.52
Book value per share
$0.3
Revenue per share
$0.85
TBVPS
$0.47
Total assets
$16.73M
Total liabilities
$6.15M
Debt
$295,000
Equity
$10.58M
Working capital
$10.21M
Debt to equity
0.03
Current ratio
2.7
Quick ratio
2.42
Net debt/EBITDA
1.05
Margins
Efficiency
Dividend
EBITDA margin
-44.4%
Gross margin
100%
Net margin
-46%
Operating margin
-47.2%
Return on assets
-46.8%
Return on equity
-74.4%
Return on invested capital
-290.5%
Return on capital employed
-127%
Return on sales
-44.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
EQ stock price
How has the Equillium stock price performed over time
Intraday
3.36%
1 week
-1.76%
1 month
-12.14%
1 year
-65.19%
YTD
-50.68%
QTD
-5.94%
Financial performance
How have Equillium's revenue and profit performed over time
Revenue
$30.41M
Gross profit
$30.41M
Operating income
-$14.35M
Net income
-$13.99M
Gross margin
100%
Net margin
-46%
EQ's operating margin has plunged by 135% from the previous quarter and by 36% YoY
Equillium's net margin has shrunk by 135% QoQ and by 44% YoY
The operating income has dropped by 74% since the previous quarter and by 9% year-on-year
EQ's net income has dropped by 73% since the previous quarter and by 15% year-on-year
Price vs fundamentals
How does EQ's price correlate with its fundamentals
Growth
What is Equillium's growth rate over time
Valuation
What is Equillium stock price valuation
P/E
N/A
P/B
1.24
P/S
0.43
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-0.03
The EPS has dropped by 74% since the previous quarter and by 14% year-on-year
The equity has contracted by 50% YoY and by 45% from the previous quarter
The price to book (P/B) is 27% lower than the 5-year quarterly average of 1.7 and 4.6% lower than the last 4 quarters average of 1.3
The stock's P/S is 28% less than its last 4 quarters average of 0.6
Equillium's revenue has decreased by 26% from the previous quarter and by 20% YoY
Efficiency
How efficient is Equillium business performance
The return on sales has dropped by 138% since the previous quarter and by 49% year-on-year
The company's return on assets has shrunk by 113% QoQ and by 101% YoY
The ROE has plunged by 98% from the previous quarter and by 45% YoY
The ROIC is up by 13% year-on-year
Dividends
What is EQ's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for EQ.
Financial health
How did Equillium financials performed over time
The total assets is 172% greater than the total liabilities
EQ's total liabilities has plunged by 73% YoY and by 6% from the previous quarter
The total assets has dropped by 62% year-on-year and by 35% since the previous quarter
Equillium's debt is 97% lower than its equity
Equillium's debt has shrunk by 59% YoY and by 23% QoQ
The equity has contracted by 50% YoY and by 45% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.